EMA Validates Immunome’s Varegacestat Marketing Application
The EMA validated Immunome’s marketing application for varegacestat to treat adults with desmoid tumors, starting centralized review. The FDA has already accepted the NDA, with a PDUFA date of April 28, 2027.